BACKGROUND: The occurrence of stressful life events (SLEs) has been shown to predict response to antidepressants; however, results are inconsistent. There is some evidence to suggest that SLEs prior to treatment are associated with greater cognitive symptoms at baseline and may therefore predict changes in these symptoms specifically. METHODS: GENDEP, a prospective part-randomised pharmacogenomics trial, collected longitudinal data on the symptoms of patients with major depression treated with either aselective serotonin reuptake inhibitor (SSRI, escitalopram) or a tricyclic antidepressant (TCA, nortriptyline). Data on life events experienced in the 6 months preceding treatment measured using the List of Threatening Experiences Questionnaire (LTE-Q) were available for 728 participants. RESULTS: Both the occurrence and number of SLEs were associated with greater cognitive but not mood or neurovegetative symptoms prior to treatment. Those who reported SLEs also experienced a greater decline in cognitive symptoms during treatment with escitalopram, but not with nortriptyline. LIMITATIONS: Life events were measured retrospectively using a self-report checklist and are therefore subject to a number of biases especially in the context of depressive illness. CONCLUSIONS: These findings are in line with cognitive theories of depression and suggest that symptomatic heterogeneity may have contributed to inconsistencies in studies reported to date. Our results also tentatively suggest a clinically relevant drug specific effect of SLEs. Specifically, those reporting stress may benefit more from treatment with SSRIs than TCAs.
RCT Entities:
BACKGROUND: The occurrence of stressful life events (SLEs) has been shown to predict response to antidepressants; however, results are inconsistent. There is some evidence to suggest that SLEs prior to treatment are associated with greater cognitive symptoms at baseline and may therefore predict changes in these symptoms specifically. METHODS: GENDEP, a prospective part-randomised pharmacogenomics trial, collected longitudinal data on the symptoms of patients with major depression treated with either a selective serotonin reuptake inhibitor (SSRI, escitalopram) or a tricyclic antidepressant (TCA, nortriptyline). Data on life events experienced in the 6 months preceding treatment measured using the List of Threatening Experiences Questionnaire (LTE-Q) were available for 728 participants. RESULTS: Both the occurrence and number of SLEs were associated with greater cognitive but not mood or neurovegetative symptoms prior to treatment. Those who reported SLEs also experienced a greater decline in cognitive symptoms during treatment with escitalopram, but not with nortriptyline. LIMITATIONS: Life events were measured retrospectively using a self-report checklist and are therefore subject to a number of biases especially in the context of depressive illness. CONCLUSIONS: These findings are in line with cognitive theories of depression and suggest that symptomatic heterogeneity may have contributed to inconsistencies in studies reported to date. Our results also tentatively suggest a clinically relevant drug specific effect of SLEs. Specifically, those reporting stress may benefit more from treatment with SSRIs than TCAs.
Authors: Maju M Koola; Evangelia M Tsapakis; Padraig Wright; Shubulade Smith; Robert W Kerwin Rip; Katie L Nugent; Katherine J Aitchison Journal: J Psychopharmacol Date: 2014-03-04 Impact factor: 4.153
Authors: Annamaria Cattaneo; Massimo Gennarelli; Rudolf Uher; Gerome Breen; Anne Farmer; Katherine J Aitchison; Ian W Craig; Christoph Anacker; Patricia A Zunsztain; Peter McGuffin; Carmine M Pariante Journal: Neuropsychopharmacology Date: 2012-09-19 Impact factor: 7.853
Authors: Karim Malki; Robert Keers; Maria Grazia Tosto; Anbarasu Lourdusamy; Lucia Carboni; Enrico Domenici; Rudolf Uher; Peter McGuffin; Leonard C Schalkwyk Journal: BMC Med Date: 2014-05-07 Impact factor: 8.775
Authors: Dávid Kovacs; Xénia Gonda; Péter Petschner; Andrea Edes; Nóra Eszlari; György Bagdy; Gabriella Juhasz Journal: Ann Gen Psychiatry Date: 2014-06-13 Impact factor: 3.455
Authors: Annamaria Cattaneo; Clarissa Ferrari; Rudolf Uher; Luisella Bocchio-Chiavetto; Marco Andrea Riva; Carmine M Pariante Journal: Int J Neuropsychopharmacol Date: 2016-09-30 Impact factor: 5.176
Authors: Edgar A Vares; Giovanni A Salum; Lucas Spanemberg; Marco A Caldieraro; Lívia H de Souza; Roberta de P Borges; Marcelo P Fleck Journal: Braz J Psychiatry Date: 2015-11-24 Impact factor: 2.697